Top Markets
#1 GoPlus Security GoPlus Security +40.91%
#2 Tutorial Tutorial +21.27%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.85%
#4 Pons Pons +18.51%
#5 Status Status +14.44%
#6 SkyAI SkyAI +13.40%
#7 Verus Coin Verus Coin +13.11%
#8 Nillion Nillion +8.72%
#9 BankrCoin BankrCoin +8.66%
#10 Talus Network Talus Network +8.55%
Coin of the day
GoPlus Security GoPlus Security
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Vectus Biosystems Limited Vectus Biosystems Limited

Vectus Biosystems Limited

VBS
Pozycja w akcjach #33746
Vectus Biosystems Limited, an Australian medical research and development firm,... Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
Cena akcji
$0.11284557
Kapitalizacja rynkowa
$6.98M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
162.85%
Kraj
AU
Handel Vectus Biosystems Limited (VBS)

Kategoria

Healthcare
Zyski dla Vectus Biosystems Limited (VBS)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Vectus Biosystems Limited, obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Vectus Biosystems Limited od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE